Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | MME | P08473 | 4/20 | 0.38 |
| ▸ | CPA1 | P15085 | 2/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736327 | 1.00 | ACE (0.50) | ACEMAPTALDH1A1TDP1LMNA | |
| SCHEMBL8459221 | 0.80 | CNR1 (0.41) | ALDH1A1TDP1CNR1MMEKCNK3 | |
| SCHEMBL10311688 | 0.80 | CNR1 (0.41) | ALDH1A1TDP1CNR1MMEKCNK3 | |
| SCHEMBL10311692 | 0.80 | CNR1 (0.41) | ALDH1A1TDP1CNR1MMEKCNK3 | |
| SCHEMBL1582575 | 0.78 | CNR1 (0.40) | ALDH1A1TDP1LMNACNR1KCNK3 | |
| SCHEMBL9240957 | 0.76 | DPP4 (0.50) | ALDH1A1TDP1CNR1KCNK3THRB | |
| SCHEMBL13351173 | 0.76 | DPP4 (0.50) | ALDH1A1TDP1CNR1KCNK3THRB | |
| SCHEMBL16481095 | 0.76 | CNR1 (0.39) | ALDH1A1TDP1CNR1MMEKCNK3 | |
| SCHEMBL9240954 | 0.76 | DPP4 (0.50) | ALDH1A1TDP1CNR1KCNK3THRB | |
| SCHEMBL5089424 | 0.76 | ACE (0.46) | ACEMAPTALDH1A1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ACE 2442/4885MAPT 290/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.